Introduction
Protein C (PC) anticoagulation pathway is established as an important regulatory mechanism of blood coagulation [1, 2] . Protein C functions as an anticoagulant when converted to an active serine protease form on the endothelial cell surface. After its activation protein C downregulates thrombin formation via inactivation of the coagulation factors Va and VIIIa [3] . Recent evidence has revealed that the basic components of protein C anticoagulation system: activated protein C (aPC), thrombomodulin, endothelial protein C receptor (EPSR) and protein S have specific activities that impact not only on coagulation but also on inflammation, fibrinolysis, cell survival, and cell proliferation [4, 5] . Similar to all elements of the hemocoagulation system this anticoagulation pathway is subjected to a precise regulation.
Undoubtedly, the endocrine system is substantially involved in this regulation. There is a lot of clinical and experimental evidence about relationships of various hormonal disorders and hemostasis. However, data about thyroid hormonal axis on this topic are relatively limited, at times controversial and are mainly based on clinical observations on patients with hyperand hypothyroidism [6] [7] [8] [9] . Various abnormalities have been described, ranging from subclinical laboratory abnormalities to major hemorrhages or fatal thromboembolic events. The influence of thyroid hormone on the coagulation/fibrinolytic system is mainly mediated by the interaction between the hormone and its receptors. According to the recent literature, most of the hemostatic abnormalities associated with thyroid dysfunction are the consequence of direct effects of thyroid hormones on the synthesis of various hemostatic parameters. Thyroid autoimmunity may also modify the processes of primary and secondary hemostasis. Other factors may determine both hyper and hypocoagulability reported by different studies in patients with hyperthyroidism and hypothyroidism. Various clotting factors and platelet functions are reported to be modulated in thyroid disorders. The recent report of Debeij et al., 2010 [10] and several earlier studies cited above emphasize the effect of thyroid hormones on fibrinogen, FVIII, vWF, and PC. No data about the direct role of thyrotropin-releasing hormone (TRH) and thyroid-stimulating hormone (TSH) in hemostasis are presently available, although direct TSH effects on various peripheral tissues (bone, adipocytes, liver) are reported [11, 12] .
The hormones of thyroid hormonal axis (TRH, TSH, T3 and T4) are involved in a complex inter regulation via multiple positive and negative shorter or longer feedback mechanisms [12] . They perform various direct, indirect, metabolic or pleiotropic effects. This makes the precise definition of their effects on hemostasis rather difficult. Moreover, their pharmacodynamics and pharmacokinetics depend on complex plasma protein binding and enzyme degradation and other clearance factors. Data in the published literature indicate three day treatment in rats is enough to observe the basic metabolic, synthetic and other regulatory effects by all four hormones identified [12] [13] [14] [15] .
This study aimed to investigate the effects of the hormones of the hypothalamic-pituitary-thyroid axis (TRH, TSH, T3 and T4), on some basic parameters of the activity of protein C anticoagulation pathway in rats.
Experimental Procedures
Experiments were carried out on 130 male Wistar rats, weighing 200 -220 g, following the requirements of the European Convention for the Protection of Experimental Animals (Protection of animals used for experimental purposes, Council Directive 86/609/ EEC of November 1986) and approved by the ethical committee of the Medical University, Varna. The rats were received from the internationally accredited vivarium of the Medical University, Varna, Bulgaria. The animals were fed by standard briquette food and water ad libitum. Five groups each containing 13 rats were used for determination of total and free PS, sEPCR, PC. Another set of 5 groups were used for activated PC because of the large blood volumes needed. The hormones were injected subcutaneously once daily for three consecutive days. In order to avoid possible diurnal effects the animals were exposed to 12/12 hour dark/light cycles and hormone application, as well as blood acquisition performed at defined times of the day. The first group of rats were injected by thyrotropin releasing hormone (TRH), acetate salt (Sigma, minimum activity 97%), in a dose of 0.06 mg/kg body mass; the second group -by bovine thyroidstimulating hormone (TSH, activity of 2 IU/mg, Sigma), in a dose of 1 IU/kg, the third and the forth groupsrespectively by Liothyroninum (T3) and Levothyroxinum (T4) provided by VEB Berlin -Chemie, Germany -0.08 mg/kg. The doses used were determined on the basis of published literature and through preliminary analysis of logarithmic dose-effect dependence, as previously described [16] . The fifth (control) group were injected with the same schema and volume per kg.
The necessary blood volume from a rat was obtained in a plastic syringe through a cardiac puncture under ether narcosis. Sodium citrate (0.11 mol/l) was used as an anticoagulant (blood/citrate ratio 9:1). The citrated blood was centrifuged for 10 min at 1500 x g. The citrated plasma (the supernatant) was separated and stored at 4ºС in haemostatic test-tubes. The coagulation parameters were determined within 2 hours.
Parameters of protein C anticoagulation pathway were measured as follows: total protein S using Asserachrom ® enzyme-linked immunosorbent assay (Diagnostica Stago, France); free protein S by Imulse ® monoclonal free protein S antigen ELISA assay (Diagnostica Stago, France); protein S activity by ELISA kit for quantitative determination (Diagnostica Stago, France); Soluble form of endothelial protein C receptor (sEPCR) by Asserachrom ® ELISA kit (Diagnostica Stago, France); protein C antigen (protein C:Ag) and protein C activity by ELISA kits (Diagnostica Stago, France).
Another set of rats (other five groups, n=65) were injected by the same hormones with the same schema. They were used only for determination of activated protein C, because the volume of blood from a rat necessary for measurement of the parameter was 4.5 ml. The method used described by España et al. [17] without any modifications, based on ELISA detection of the activated protein C complex to its major plasma inhibitor, protein C inhibitor.
All ELISA methods were performed according to the requirements of the manufacturer. ELISA assays were done in duplicate and each sample was measured twice. Optical densities were recorded on Organon Teknika ELISA reader and the corresponding parameters (activity, concentration) were calculated by 4 parameter fit logarithmic curves by the means of the software of the ELISA reader. Activities of the parameters evaluated are presented as % of activity.
Histological screening for microhemorrhages and intravascular thrombosis was performed. Slices from internal organs (liver, kidney and intestine) were prepared and stained by hematoxylin-eosin and by Weigert for fibrin [18] for the detection of micro-hemorrhages and/ or intravascular coagulation.
All data were analyzed by variation analysis using GraphPad Prism 4 software. The Student t-test and Fisher test were used for hypothesis testing. Values of P less than 0.05 were considered significant.
Results and Discussion
Protein C:Ag was significantly increased in this study by TRH and TSH from 2.25±0.14 µg/ml in the control group to 3.22±0.12 and 3.92±0.24 µg/ml respectively. T3 and T4 did not influence this parameter. Activated Protein C is one of the key elements of the protein C anticoagulation pathway [19] . It is a vitamin K-dependent coagulation protein synthesized predominantly in the liver circulating biologically inactive in blood. Activation of PC to activated PC is catalyzed by the thrombin/ thrombomodulin complex, or, less efficiently by thrombin alone. In its anticoagulant role, aPC catalyzes limited proteolytic inactivation of coagulation factors FV(a) and FVIII(a) in the presence of Ca 2+ , phospholipids, and the cofactor, protein S, thus, attenuating production of thrombin. EPCR enhances the activation of PC by binding the protein on cell surfaces and presenting it to the thrombin/thrombomodulin complex [20] . aPC also plays an indirect profibrinolytic role through its property of limiting thrombin formation.
Our results indicate protein C:Ag plasma level is significantly elevated in groups of rats treated by TRH and TSH, but not significantly altered by T3 and T4. This may be an indication that both TRH and TSH increase protein C:Ag biosynthesis without the mediation of T3 and T4, i.e. they perform autonomous effects. This hypothesis is reasonable, bearing in mind reported direct extra thyroid effects of TSH on adipocytes, osteoblasts, and hepatocytes, as well as the expression of TSH on liver receptors [11] . At present, it remains unclear whether TRH and TSH perform their stimulating effects directly or indirectly.
In this study both activated protein C and protein C activity were increased by all the hormones applied. These results indicate that all hormones of the hypothalamic-pituitary-thyroid axis do increase the activity of protein C anticoagulation pathway. As mentioned above, transition of the inactive protein C to activated protein C is accomplished via the complex thrombin/thrombomodulin. Protein C concentration, protein C activity, and activated protein C are different parameters indicating the synthesis and steps of protein C activation. A special emphasis should be made of the specific difference between activated PC and its activity. The circulating form of the activated PC as an antigen concentration does not always coincide with the activity measured [17] . However, in this study we found similar effects of the hormones studied on both parameters. The endothelial cell protein C receptor (EPCR) functions as an important regulator of the protein C anticoagulant pathway by binding protein C and further enhancing activation by the thrombin-thrombomodulin complex [20] . EPCR binds to both protein C and activated protein C (APC) with high affinity. A soluble form of this receptor (sEPCR) circulates in plasma and has been shown to bind protein C and aPC with an affinity A B C similar to that of intact membrane-bound EPCR [21] . In contrast to membrane-bound EPCR, sEPCR inhibits protein C activation over large vessel endothelium. This presumably reflects competition between the sEPCR and cell surface EPCR. sEPCR also inhibits aPC anticoagulant activity, and elevations in the level of plasma sEPCR presumably reflect thrombin activation of large vessel endothelium.
We have studied the effects of the hormones of thyroid hormonal axis on the soluble form of the endothelial cell protein C receptor, which is considered to inactivate the anticoagulant activity of the activated protein C. sEPCR was significantly reduced in all groups by all four hormones. This finding is consistent with the increased protein C activation.
The anticoagulant activity of the activated protein C is further achieved after its association by its cofactor protein S which is followed by proteolytically destroying coagulation factors Va and VIIIa and suppression of thrombin formation [22, 23] . The results of our study indicate the hormones of the hypothalamic-pituitarythyroid axis exert additional effect on protein C anticoagulation pathway via protein S. Here the total protein S plasma levels were elevated only after TRH and TSH application, while free protein S and protein S activity were stimulated by all the hormones. One striking observation was the effect of TRH and TSH strongly increasing total protein S plasma levels independently of T3 and T4, similar to their effect on protein C:Ag. This suggests TRH and TSH may be directly engaged in this anticoagulation mechanism via stimulation biosynthesis of both protein C and protein S.
The significant rise of protein C activity and its cofactor protein S allow us to presume that the activity of protein C anticoagulation pathway is increased.
Overall this may suggest a general tendency of hypocoagulability which is supported by similar findings in our previous studies on the same hormones and other hemocoagulation parameters in rats [16, 24] .
The effects of the hormones observed in this study may result from: (a) direct or indirect effects on hepatocytes where PC and PS biosynthesis take place; (b) impact on regulation of hormonal secretion performed via feedback mechanisms coherent for the hormones of the thyroid hormonal axis, effects on their metabolism, clearance or receptor expression; and (c) secretion, transport, metabolism, breakdown, clearance and activation of the variables studied [12] . Obviously, the most plausible hypothesis is of a stimulating effect of the hormones PC and PS liver production.
In conclusion, the results of this study demonstrate that the hormones of the hypothalamic-pituitary-thyroid axis increase activated protein C, free protein S and protein S activity, and reduce the soluble endothelial protein C receptor. Protein C antigen and total protein S were significantly elevated only by thyrotropin-releasing hormone and thyroid-stimulating hormone, but were not affected by T3 and T4 treatment. The data indicate the hypothalamic-pituitary-thyroid axis is involved in the regulation of protein C anticoagulation system in rats by activation of anticoagulation via this pathway.
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